Qunibi W, Abulrub D, Shaheen F, el-Din A B, Alfurayh O, Almeshari K
Department of Medicine, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia.
Clin Transplant. 1995 Aug;9(4):317-21.
Renal transplantation offers patients with end-stage renal disease the best opportunity for rehabilitation and long-term survival. However, there is a critical shortage of transplantable kidneys worldwide. This plays well into the hands of transplanters and entrepreneurs involved in commercial renal transplantation, particularly in India. This practice has been condemned by all transplant societies. In our fight against rampant commercialism in renal transplantation, we sought to describe feelings of patients who had received transplants in India, and the difficulties they faced during their stay there. The results show that the two reasons that motivated patients to go to India were lack of living-related donors and the need for prompt transplant. More than half of the patients did not meet their donors. Their experience, however, has been largely positive except for some negative feelings toward the broker and the standard of hospital hygiene. The total cost of the transplant was far less than that in the West but, despite that, some patients felt financially exploited. Communication with them was poor, as most patients did not get adequate pretransplant education and were not informed of possible complications including rejection and graft loss. Furthermore, almost half of the patients were not given medical reports. These results substantiate the impression that CRT in India does not conform to the high standards of renal transplant medicine.
肾移植为终末期肾病患者提供了康复和长期生存的最佳机会。然而,全球可用于移植的肾脏严重短缺。这对参与商业肾移植的移植医生和企业家十分有利,在印度尤其如此。这种做法受到了所有移植协会的谴责。在我们打击肾移植中猖獗的商业化行为的过程中,我们试图描述在印度接受移植的患者的感受,以及他们在当地停留期间所面临的困难。结果表明,促使患者前往印度的两个原因是缺乏亲属活体供体以及需要尽快进行移植。超过一半的患者没有见到他们的供体。然而,除了对中介人和医院卫生标准有些负面感受外,他们的经历总体上是积极的。移植的总费用远低于西方,但尽管如此,一些患者仍觉得在经济上受到了剥削。与他们的沟通很差,因为大多数患者没有得到充分的移植前教育,也没有被告知包括排斥反应和移植物丢失在内的可能并发症。此外,几乎一半的患者没有拿到医疗报告。这些结果证实了一种印象,即印度的商业肾移植不符合肾移植医学的高标准。